23.80EUR0.00%Mkt Cap: 1.69B $P/E: 2.642d ago
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap1.69B $
Enterprise Value-728.91M $
Revenue (TTM)1.08B $
Gross Profit1.18B $
Net Income (TTM)348.79M $
Revenue/Share16.34 USD
Last Price23.80 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees452
CountryDE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.64
P/E (Forward)—
PEG—
EV/EBITDA-1.18
EV/Revenue-0.68
P/S1.57
P/B0.48
EPS (TTM)9.02
EPS (Forward)—
52W Range
—
52W High23.80 EUR
52W Low23.80 EUR
Profitability
Gross Margin97.33%
Oper. Margin-359.30%
EBITDA Margin57.43%
Profit Margin28.85%
ROE9.92%
ROA9.42%
Growth
Revenue Growth-81.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-279.84M $
CapEx (TTM)15.06M $
FCF Margin13.95%
FCF Yield8.87%
Net Debt-2.43B $
Net Debt/EBITDA-3.93
Balance Sheet
Debt/Equity0.00
Current Ratio32.84
Quick Ratio32.65
Book Value/Sh49.37 EUR
Cash/Share34.11 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.65.48M
Float24.30M
Insiders25.36%
Institutions43.29%
Technical
SMA 5024.92 (-4.5%)
SMA 20026.22 (-9.2%)
Beta0.11
S&P 52W Chg18.16%
Avg Vol (30d)22
Avg Vol (10d)231
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—